Table 1.
Baseline demographic and clinical characteristics
| Variable | Level | All patients (n = 1989) |
|---|---|---|
| Visits assessed | Median (IQR) | 7 (4, 11) |
| Range | 3–66 | |
| Sex | Male | 571 (28.7%) |
| Female | 1418 (71.3%) | |
| Age at CIS | Mean (SD) | 32.9 (10.0) |
| Range | 6–68 | |
| EDSS | Median (IQR) | 1.5 (1, 2) |
| Range | 0–7.5 | |
| Affected KFS | ||
| (KFS score ≥1) | Ambulation | 208 (10.5%) |
| Pyramidal | 1134 (57.0%) | |
| Cerebellar | 528 (26.5%) | |
| Brainstem | 634 (31.9%) | |
| Sensory | 943 (47.4%) | |
| Bowel/Bladder | 304 (15.3%) | |
| Visual | 485 (24.4%) | |
| Mental | 285 (14.3%) | |
| T2 lesion load | ||
| 0 | 77 (3.9%) | |
| 1–2 | 106 (5.3%) | |
| 3–8 | 1027 (51.6%) | |
| ≥9 | 540 (27.1%) | |
| Not available | 239 (12.0%) | |
| Age at DMT start (years) | Mean (SD) | 33.2 (9.9) |
| Range | 6.4–67.6 | |
| First DMT | ||
| (prior to worsening) | No DMT | 650 (32.7%) |
| IFNβ-1a IM | 373 (18.8%) | |
| IFNβ-1a SC | 494 (24.8%) | |
| IFNβ-1b | 232 (11.7%) | |
| Glatiramer Acetate | 208 (10.5%) | |
| Fingolimod | 4 (0.2%) | |
| Natalizumab | 28 (1.4%) | |
| PTT | ||
| (censored at progression) | 0% | 666 (33.5%) |
| >0–50% | 349 (17.5%) | |
| >50–80% | 519 (26.1%) | |
| >80% | 455 (22.9%) | |
CIS, clinically isolated syndrome; EDSS, Expanded Disability Status Scale; KFS, Kurtzke Functional System; DMT, disease-modifying therapy; PTT, proportion of time on treatment; IQR, interquartile range; IM, intramuscular; SC, subcutaneous.